MA28004A1 - Traitement du sevrage de la dependance - Google Patents
Traitement du sevrage de la dependanceInfo
- Publication number
- MA28004A1 MA28004A1 MA28830A MA28830A MA28004A1 MA 28004 A1 MA28004 A1 MA 28004A1 MA 28830 A MA28830 A MA 28830A MA 28830 A MA28830 A MA 28830A MA 28004 A1 MA28004 A1 MA 28004A1
- Authority
- MA
- Morocco
- Prior art keywords
- buprenorphine
- dosage form
- dosage
- days
- dosing period
- Prior art date
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 7
- 229960001736 buprenorphine Drugs 0.000 abstract 7
- 239000002552 dosage form Substances 0.000 abstract 4
- 239000006211 transdermal dosage form Substances 0.000 abstract 3
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B2101/00—Type of solid waste
- B09B2101/65—Medical waste
- B09B2101/68—Transdermal patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Reverberation, Karaoke And Other Acoustics (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Drying Of Semiconductors (AREA)
- Cephalosporin Compounds (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
Abstract
On décrit des régimes de dosage de buprénorphine pour traiter le syndrome du sevrage et de l'abstinence chez une patiente enceinte dépendant d'une drogue ou tolérant un opioïde. Le procédé comporte le traitement du syndrome de sevrage et de l'abstinence de la patiente par l'administration transdermique d'une quantité efficace de buprénorphine pour réduire les syndromes de sevrage. On peut par exemple administrer au patient une première forme de dosage transdermique contenant de la buprénorphine pour une première période de dosage qui n'est pas plus longue que 5 jours; une seconde forme de dosage transdermique contenant de la buprénorphine pour une première période de dosage qui n'est pas plus longue que 5 jours , où la seconde forme de dosage comprend le même dosage de buprénorphine que , ou un plus grand dosage de buprénorphine que ladite première forme de dosage; et une troisième forme de dosage transdermique contenant de la buprénorphine pour une troisième période de dosage pour au moins 2 jours, où la troisième forme de dosage comprend un plus grand dosage de buprénorphine que la seconde forme de dosage.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49040703P | 2003-07-25 | 2003-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28004A1 true MA28004A1 (fr) | 2006-07-03 |
Family
ID=34115390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28830A MA28004A1 (fr) | 2003-07-25 | 2006-02-23 | Traitement du sevrage de la dependance |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8637073B2 (fr) |
| EP (1) | EP1646328B1 (fr) |
| JP (2) | JP2007500134A (fr) |
| KR (1) | KR100829492B1 (fr) |
| CN (1) | CN1829482B (fr) |
| AT (1) | ATE375149T1 (fr) |
| AU (1) | AU2004261182B2 (fr) |
| BR (1) | BRPI0412931A (fr) |
| CA (1) | CA2530005C (fr) |
| CY (1) | CY1107262T1 (fr) |
| DE (1) | DE602004009449T2 (fr) |
| DK (1) | DK1646328T3 (fr) |
| EA (1) | EA009921B1 (fr) |
| ES (1) | ES2295929T3 (fr) |
| GE (1) | GEP20125454B (fr) |
| HR (1) | HRP20070476T3 (fr) |
| IL (1) | IL173346A (fr) |
| IS (1) | IS2630B (fr) |
| MA (1) | MA28004A1 (fr) |
| MX (1) | MXPA06000991A (fr) |
| NO (1) | NO333189B1 (fr) |
| NZ (1) | NZ545505A (fr) |
| PL (1) | PL1646328T3 (fr) |
| PT (1) | PT1646328E (fr) |
| SI (1) | SI1646328T1 (fr) |
| UA (1) | UA81056C2 (fr) |
| WO (1) | WO2005011579A2 (fr) |
| ZA (1) | ZA200510069B (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| US7270830B2 (en) * | 2002-12-13 | 2007-09-18 | Purdue Pharma L.P. | Transdermal buprenorphine dosage regimen for analgesia |
| EP1913938A1 (fr) * | 2002-12-13 | 2008-04-23 | Euro-Celtique S.A. | Posologie transdermique de buprénorphine pour l'analgésie |
| DE602004009449T2 (de) | 2003-07-25 | 2008-07-24 | Euro-Celtique S.A. | Behandlung von entzug |
| KR20080058433A (ko) * | 2005-09-30 | 2008-06-25 | 티티아이 엘뷰 가부시키가이샤 | 오피오이드 작용제 및/또는 오피오이드 길항제를 이용한경피 약물 전달 시스템, 장치 및 방법 |
| US9700552B2 (en) * | 2008-02-28 | 2017-07-11 | Syntropharma Limited | Pharmaceutical compositions for treatment of addiction |
| US8163731B2 (en) * | 2008-08-20 | 2012-04-24 | Rhodes Technologies | Method and dosage regimens for eliminating a chemical substance in blood |
| US9879204B2 (en) | 2010-03-17 | 2018-01-30 | Method Products, Pbc | Liquid cleaning compositions with lower freezing point |
| US11236351B2 (en) | 2010-05-17 | 2022-02-01 | Dow Agrosciences Llc | Production of DHA and other LC PUFAs in plants |
| TW201307553A (zh) | 2011-07-26 | 2013-02-16 | 陶氏農業科學公司 | 在植物中生產二十二碳六烯酸（ｄｈａ）及其他長鏈多元不飽和脂肪酸（ｌｃ－ｐｕｆａ）之技術 |
| ES2716570T3 (es) | 2012-04-17 | 2019-06-13 | Purdue Pharma Lp | Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| EP3400066B1 (fr) * | 2016-01-08 | 2021-07-28 | Ohio State Innovation Foundation | Traitements et prévention du syndrome d'abstinence néonatale aux opioïdes |
| JP2020526500A (ja) | 2017-06-30 | 2020-08-31 | パーデュー、ファーマ、リミテッド、パートナーシップ | 治療方法及びその剤形 |
| CN107648234A (zh) * | 2017-08-04 | 2018-02-02 | 中国人民解放军第二军医大学 | 一种治疗吗啡成瘾戒断症状的阿片类药物组合物 |
| CA3066284A1 (fr) * | 2018-04-09 | 2019-10-17 | Katana Pharmaceuticals, Inc. | Compositions d'ocytocine et methodes d'utilisation |
| AU2020342591A1 (en) | 2019-09-02 | 2022-03-03 | Camurus Ab | Formulations and treatment methods |
| EP4284506A4 (fr) | 2021-02-01 | 2024-12-25 | Clear Scientific, Inc. | Composés de séquestration pour le traitement d'un trouble de l'usage d'une substance et leurs utilisations |
| EP4568672A2 (fr) * | 2022-08-12 | 2025-06-18 | Bioventures, Llc | Buprénorphine deutérée en tant qu'agent protecteur pour des sujets foetaux contre une exposition aux opioïdes agonistes complets |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4058599A (en) | 1973-02-24 | 1977-11-15 | Bayer Aktiengesellschaft | Ethyleneimine inactivated organisms |
| DE3939376C1 (fr) | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
| US5075341A (en) * | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
| EP0432945A1 (fr) * | 1989-12-12 | 1991-06-19 | Warner-Lambert Company | Système d'administration transdermique pour le traitement de la cocainomanie et de l'héroinomanie |
| US5272149A (en) * | 1992-05-05 | 1993-12-21 | Stalling Reginald W | Symptom controlled receptor substitution for addiction withdrawl |
| JPH06183956A (ja) * | 1992-12-24 | 1994-07-05 | Teisan Seiyaku Kk | 安定な貼付用の製剤 |
| JP2819236B2 (ja) * | 1994-05-06 | 1998-10-30 | 日東電工株式会社 | 経皮吸収製剤 |
| EP0821957A3 (fr) | 1996-08-01 | 1998-04-22 | Eli Lilly And Company | Utilisation de la 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tétrahydro-1-méthylpyridine (xanoméline) pour traiter l'abus de drogues |
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| KR100383252B1 (ko) | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 |
| AU2002348135A1 (en) * | 2001-10-31 | 2003-05-12 | Recovery Pharmaceuticals, Inc. | Methods for the treatment of addiction |
| PT1485051E (pt) | 2002-03-20 | 2008-07-09 | Euro Celtique Sa | Processo de administração da buprenorfina para o tratamento da depressão |
| US7270830B2 (en) | 2002-12-13 | 2007-09-18 | Purdue Pharma L.P. | Transdermal buprenorphine dosage regimen for analgesia |
| WO2004103317A2 (fr) | 2003-05-15 | 2004-12-02 | Euro-Celtique S.A. | Regime posologique pour le traitement de la diarrhee par administration de buprenorphine par voie transdermique |
| DE602004009449T2 (de) | 2003-07-25 | 2008-07-24 | Euro-Celtique S.A. | Behandlung von entzug |
-
2004
- 2004-07-26 DE DE602004009449T patent/DE602004009449T2/de not_active Expired - Lifetime
- 2004-07-26 US US10/566,121 patent/US8637073B2/en active Active
- 2004-07-26 JP JP2006521307A patent/JP2007500134A/ja active Pending
- 2004-07-26 PL PL04779186T patent/PL1646328T3/pl unknown
- 2004-07-26 MX MXPA06000991A patent/MXPA06000991A/es active IP Right Grant
- 2004-07-26 SI SI200430545T patent/SI1646328T1/sl unknown
- 2004-07-26 AT AT04779186T patent/ATE375149T1/de active
- 2004-07-26 KR KR1020067001688A patent/KR100829492B1/ko not_active Expired - Fee Related
- 2004-07-26 EP EP04779186A patent/EP1646328B1/fr not_active Expired - Lifetime
- 2004-07-26 GE GEAP20049184A patent/GEP20125454B/en unknown
- 2004-07-26 WO PCT/US2004/024010 patent/WO2005011579A2/fr not_active Ceased
- 2004-07-26 ES ES04779186T patent/ES2295929T3/es not_active Expired - Lifetime
- 2004-07-26 NZ NZ545505A patent/NZ545505A/en not_active IP Right Cessation
- 2004-07-26 PT PT04779186T patent/PT1646328E/pt unknown
- 2004-07-26 AU AU2004261182A patent/AU2004261182B2/en not_active Ceased
- 2004-07-26 CA CA2530005A patent/CA2530005C/fr not_active Expired - Fee Related
- 2004-07-26 DK DK04779186T patent/DK1646328T3/da active
- 2004-07-26 BR BRPI0412931-8A patent/BRPI0412931A/pt not_active Application Discontinuation
- 2004-07-26 CN CN2004800215633A patent/CN1829482B/zh not_active Expired - Fee Related
- 2004-07-26 UA UAA200602136A patent/UA81056C2/uk unknown
- 2004-07-26 EA EA200600200A patent/EA009921B1/ru not_active IP Right Cessation
- 2004-07-26 HR HR20070476T patent/HRP20070476T3/xx unknown
-
2005
- 2005-12-12 ZA ZA200510069A patent/ZA200510069B/en unknown
- 2005-12-19 IS IS8187A patent/IS2630B/is unknown
-
2006
- 2006-01-24 IL IL173346A patent/IL173346A/en not_active IP Right Cessation
- 2006-02-23 MA MA28830A patent/MA28004A1/fr unknown
- 2006-02-24 NO NO20060913A patent/NO333189B1/no not_active IP Right Cessation
-
2008
- 2008-01-08 CY CY20081100020T patent/CY1107262T1/el unknown
-
2011
- 2011-08-18 JP JP2011179129A patent/JP2011252020A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107262T1 (el) | Θεραπεια της εξαρτησης στερησης | |
| ES2224430T3 (es) | Noribogaina en el tratamiento del dolor y de la toxicomania. | |
| ATE302003T1 (de) | Zubereitungen enthaltend apomorphin und sildenafil und ihre verwendung zur behandlung von erektiler dysfunktion | |
| CY1108217T1 (el) | Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης | |
| RU2008138381A (ru) | Режимы дозирования адреналина | |
| JP2011252020A5 (fr) | ||
| JP2007500134A5 (fr) | ||
| JP2004537500A5 (fr) | ||
| ATE405272T1 (de) | Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin | |
| IL318374A (en) | Methods of administering nalbuphine | |
| UA81689C2 (ru) | Способ предоперационного лечения послеоперационной боли бупренорфином | |
| DE69623316D1 (de) | Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen | |
| Naber et al. | Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients | |
| DE60125377D1 (de) | Behandlung von hepatitis c mit thymosin, interferon und ribavirin | |
| WO2008021536A3 (fr) | Procédé pour réduire les événements secondaires causés par un traitement à l'interféron alpha ou à l'interféron bêta | |
| JPH04506969A (ja) | 成人男性における不妊症又は生殖能力低下の治療方法および該方法のための製剤の使用 | |
| UA132403U (uk) | Спосіб лікування хронічних панкреатитів та реабілітації післяопераційних хворих | |
| DE60121449D1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon | |
| RU2002129097A (ru) | Комбинированные терапии с использованием активности, повреждающей сосуды | |
| RU2004114005A (ru) | Способ лечения алкогольных болезней печени |